LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
224
via thehindubusinessline.comBusiness & Companies

Granules India seeking first-to-file status for Ruxolitinib Extended-Release Tablets

FROM THE WIRE · THEHINDUBUSINESSLINE.COM

Granules India seeks first-to-file status for Ruxolitinib Extended-Release Tablets, potentially securing 180 days of US generic exclusivity pending FDA review.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPotential 180-day US generic exclusivity could support future company growth.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Granules India seeks first-to-file status for Ruxolitinib Extended-Release Tablets.
  2. 02Approval would grant 180 days of US generic exclusivity.
  3. 03FDA review decision is still pending for this formulation.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.